Search Results - "ZUPI, G"

Refine Results
  1. 1

    PARP1 is activated at telomeres upon G4 stabilization: possible target for telomere-based therapy by Salvati, E, Scarsella, M, Porru, M, Rizzo, A, Iachettini, S, Tentori, L, Graziani, G, D'Incalci, M, Stevens, M F G, Orlandi, A, Passeri, D, Gilson, E, Zupi, G, Leonetti, C, Biroccio, A

    Published in Oncogene (25-11-2010)
    “…New anti-telomere strategies represent important goals for the development of selective cancer therapies. In this study, we reported that uncapped telomeres,…”
    Get full text
    Journal Article
  2. 2

    Targeting different signaling pathways with antisense oligonucleotides combination for cancer therapy by Leonetti, C, Zupi, G

    Published in Current pharmaceutical design (01-02-2007)
    “…The evidence that cancer development is a complex and multistep process, characterized by alterations of genes involved in the regulation of proliferation,…”
    Get more information
    Journal Article
  3. 3

    Involvement of hTERT in apoptosis induced by interference with Bcl-2 expression and function by Del Bufalo, D, Rizzo, A, Trisciuoglio, D, Cardinali, G, Torrisi, M R, Zangemeister-Wittke, U, Zupi, G, Biroccio, A

    Published in Cell death and differentiation (01-11-2005)
    “…Here, we investigated the role of telomerase on Bcl-2-dependent apoptosis. To this end, the 4625 Bcl-2/Bcl-xL bispecific antisense oligonucleotide and the…”
    Get full text
    Journal Article
  4. 4

    Involvement of RB gene family in tumor angiogenesis by Gabellini, C, Del Bufalo, D, Zupi, G

    Published in Oncogene (28-08-2006)
    “…Angiogenesis, the development of new blood vessels from pre-existing vessels, represents a fundamental step in tumor progression and metastatization. The…”
    Get full text
    Journal Article
  5. 5

    In vitro and in vivo antitumor efficacy of docetaxel and sorafenib combination in human pancreatic cancer cells by Ulivi, P, Arienti, C, Zoli, W, Scarsella, M, Carloni, S, Fabbri, F, Tesei, A, Chiadini, E, Orlandi, A, Passeri, D, Zupi, G, Milandri, C, Silvestrini, R, Amadori, D, Leonetti, C

    Published in Current cancer drug targets (01-09-2010)
    “…The response of pancreatic cancer to treatments remains unsatisfactory, highlighting the need for more effective therapeutic regimens. Sorafenib, an orally…”
    Get more information
    Journal Article
  6. 6

    Evaluation of multiple bio‐pathological factors in colorectal adenocarcinomas: Independent prognostic role of p53 and bcl‐2 by Buglioni, Simonetta, D'Agnano, Igea, Cosimelli, Maurizio, Vasselli, Stefania, D'Angelo, Carmen, Tedesco, Manfredo, Zupi, Gabriella, Mottolese, Marcella

    Published in International journal of cancer (22-12-1999)
    “…About 40% of patients with colorectal carcinoma will develop local or distant tumour recurrences. Integrated analyses of bio‐pathological markers, predictive…”
    Get full text
    Journal Article
  7. 7

    relA over-expression reduces tumorigenicity and activates apoptosis in human cancer cells by RICCA, A, BIROCCIO, A, TRISCIUOGLIO, D, CIPPITELLI, M, ZUPI, G, DEL BUFALO, D

    Published in British journal of cancer (14-12-2001)
    “…We previously demonstrated that bcl-2 over-expression increases the malignant behaviour of the MCF7 ADR human breast cancer cell line and enhances nuclear…”
    Get full text
    Journal Article
  8. 8

    Bcl-2 has differing effects on the sensitivity of breast cancer cells depending on the antineoplastic drug used by Del Bufalo, D, Biroccio, A, Trisciuoglio, D, Bruno, T, Floridi, A, Aquino, A, Zupi, G

    Published in European journal of cancer (1990) (01-12-2002)
    “…The aim of this paper was to evaluate the role of bcl-2 in the susceptibility of the MCF7 ADR human breast carcinoma line overexpressing the P-170 glycoprotein…”
    Get full text
    Journal Article
  9. 9
  10. 10
  11. 11

    A role for c-myc in DNA damage-induced apoptosis in a human TP53-mutant small-cell lung cancer cell line by Supino, R, Perego, P, Gatti, L, Caserini, C, Leonetti, C, Colantuono, M, Zuco, V, Carenini, N, Zupi, G, Zunino, F

    Published in European journal of cancer (1990) (01-11-2001)
    “…Based on the role of p53 in the control of apoptosis following DNA damage, the status of the TP53 gene has been implicated as a major determinant of tumour…”
    Get full text
    Journal Article
  12. 12

    Inhibition of leukaemia cell proliferation by folic acid-polylysine-mediated introduction of c-myb antisense oligodeoxynucleotides into HL-60 cells by CITRO, G, SZCZYLIK, C, GINOBBI, P, ZUPI, G, CALABRETTA, B

    Published in British journal of cancer (01-03-1994)
    “…The inhibitory effect of c-myb antisense oligodeoxynucleotides (ODNs) conjugated to folic acid (FA) on HL-60 cell proliferation was examined. Folic acid was…”
    Get full text
    Journal Article
  13. 13
  14. 14

    Inhibition of Leukemia Cell Proliferation by Receptor-Mediated Uptake of c-myb Antisense Oligodeoxynucleotides by Citro, Gennaro, Perrotti, Danilo, Cucco, Carla, D'Agnano, Igea, Sacchi, Ada, Zupi, Gabriella, Calabretta, Bruno

    “…Exposure of human leukemia HL-60 cells to an oligodeoxynucleotide complementary to an 18-base sequence (codons 2-7) of c-myb-encoded mRNA has previously been…”
    Get full text
    Journal Article
  15. 15

    Telomerase activity, apoptosis and cell cycle progression in ataxia telangiectasia lymphocytes expressing TCL1 by Gabellini, C, Antonelli, A, Petrinelli, P, Biroccio, A, Marcucci, L, Nigro, G, Russo, G, Zupi, G, Elli, R

    Published in British journal of cancer (15-09-2003)
    “…Individuals affected by ataxia telangiectasia (AT) have a marked susceptibility to cancer. Ataxia telangiectasia cells, in addition to defects in cell cycle…”
    Get full text
    Journal Article
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20